In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...

Donald Trump touted his “energy dominance” agenda, claiming American oil production is up 600,000 barrels per day and the US ...

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and ...

Pfizer (PFE) stock is in focus as the FDA grants full approval for its colorectal cancer drug Braftovi, developed with Ono Pharmaceutical (OPHLF). Read more here.

The CDC has assigned Mar. 18–19 as dates for the next meeting of its vaccine advisors after delaying an earlier meeting of the panel following a lawsuit. Read more here.

Using patent intelligence data from the FounderNest platform, Gonzalez highlights where small-molecule synthesis, formulation ...

Late-Stage Pipeline Advancements and Novel Therapies Position Sector for Accelerated Growth and Major Value CatalystsMarket News Updates News ...

The Food and Drug Administration will consider whether to approve Moderna’s new flu vaccine after all, resolving a dispute that had ...

The biotech is developing a drug aimed at a protein called PACAP, which has emerged as a potentially new way to prevent the ...